Mitochon Pharmaceuticals » Logo
Mitochon Pipeline
Mitochon Pipeline
Preclinical Efficacy
IND Enabling Activities
Phase I
Phase II

Parkinson’s Disease

No known genetic cause.
Movement issues, depression and later stages dementia.
Mouse Model: 6-OHDA injected into the right striatum.
0.5mpk MP101 and 8mpk MP201 was provided orally (q.d.) for 2 weeks.
The dopaminergic neurons are slowly destroyed over the course of two weeks and mice are then tested on a constant speed rotarod for duration (3-min max).
Work done at National Institute on Aging.

Our Data Shows:

Increased cortical sparing (p <0.01; 38% lesion spared).
Improved cognitive outcome (p<0.05).

Kishimoto, Y., et al., A mitochondrial uncoupler prodrug protects dopaminergic neurons and improves functional outcome in a mouse model of Parkinson's disease. Neurobiol Aging, 2020. 85: p. 123-130.

Study 2:  MP201 and MP101 (DNP) treatments reduce degeneration of substantia nigra dopaminergic neurons in the 6-OHDA mouse model of PD.

MP101 Significantly Reduces Oxidative Stress » Mitochon PharmaceuticalsMP101 Significantly Reduces Oxidative Stress » Mitochon Pharmaceuticals
**p<0.001 compared to the value for the control group.
#p<0.05, ##p<0.01 compared to the value for the placebo group.

Contact Us

We would like to hear from you if you want information on our endeavors or wish to learn more about our research efforts.